Differential Effects of Low Molecular Weight Heparin and Unfractionated Heparin on Circulating Levels of Antithrombin and Tissue Factor Pathway Inhibitor (TFPI): A Possible Mechanism for Difference in Therapeutic Efficacy
- 15 August 1998
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 91 (4) , 177-181
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Low molecular weight heparin versus unfractionated heparin following thrombolysis in myocardial infarctionJACC, 1998
- AN ENZYME LINKED IMMUNOSORPTION ASSAY FOR TISSUE FACTOR PATHWAY INHIBITORThrombosis Research, 1997
- Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysisThe American Journal of Medicine, 1996
- EnoxaparinDrugs, 1995
- Persistent activation of coagulation mechanism in unstable angina and myocardial infarction.Circulation, 1994
- Glycosaminoglycans and the regulation of blood coagulationBiochemical Journal, 1993
- Reactivation of Unstable Angina after the Discontinuation of HeparinNew England Journal of Medicine, 1992
- Heparin induces release of extrinsic: Coagulation pathway inhibitor (EPI)Thrombosis Research, 1988
- The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of actionBlood, 1988
- HEPARIN-INDUCED DECREASE IN CIRCULATING ANTITHROMBIN-IIIThe Lancet, 1977